Avelumab is an anti-PD-L1 antibody that was recently studied in metastatic ACC and led to an objective response rate of 6% and disease control rate of 48%, and almost half of study participants continued receiving mitotane during avelumab therapy [11]. This evidence concerns the gene CD274 and adrenal cortex carcinoma.